Physician profile
Anays Suarez
NPI 1063964583
$5,700.11
in general payments reported to CMS, 2019-2025
25 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $386 · 2022: $972 · 2023: $1,044 · 2024: $1,629 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,170 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,170.21 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,367.29 | 2021-2025 | |
| Janssen Biotech, INC. | $925.77 | 2021-2025 | Tremfya, Stelara, Remicade |
| Lilly USA, LLC | $418.13 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $387.38 | 2022-2025 | Sotyktu |
| Incyte Corporation | $378.83 | 2022-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $335.81 | 2021-2025 | |
| Ucb, INC. | $309.20 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $237.47 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $231.68 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $218.82 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $182.82 | 2023-2025 | Odomzo, Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $159.96 | 2024-2025 | Nemluvio |
| Vyne Pharmaceuticals INC. | $127.88 | 2021 | |
| Convatec INC. | $90.17 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $59.88 | 2024-2025 | Jublia, Arazlo, Cabtreo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.18 | 2024-2025 | Spevigo |
| Verrica Pharmaceuticals INC. | $40.44 | 2023-2024 | Ycanth |
| Leo Pharma INC. | $39.52 | 2022-2023 | Adbry |
| Amgen INC. | $24.71 | 2025 | Otezla |
| Organogenesis INC. | $22.04 | 2022 | |
| Genentech USA, INC. | $21.39 | 2023 | Erivedge |
| Smith+Nephew, INC. | $19.43 | 2024 | Oasis, Grafix Pl, Stravix |
| Dermavant Sciences, INC. | $17.49 | 2023 | Vtama |
| Nabriva Therapeutics, Plc | $17.31 | 2022 | |
| Arcutis Biotherapeutics, INC. | $14.51 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anays Suarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.